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ABSTRACT There are limited published data defining survival and treatment response in patients with
mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary
arterial hypertension (IPAH).
Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum
of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed
tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed
IPAHno-LD (n=303), and those with minor/mild emphysema or fibrosis were described as IPAHmild-LD (n=190).
Survival was significantly better in IPAHno-LD than in IPAHmild-LD (1- and 5-year survival 95% and 70%
versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAHno-LD and IPAHmild-LD,
independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon
monoxide (DLCO), lower exercise capacity and a diagnosis of IPAHmild-LD (all p<0.05). Exercise capacity and
quality of life improved (both p<0.0001) following treatment in patients with IPAHno-LD, but not IPAHmild-LD.
A proportion of patients with IPAHno-LD had a DLCO <45%; these patients had poorer survival than patients
with DLCO ⩾45%, although they demonstrated improved exercise capacity following treatment.
The presence of even mild parenchymal lung disease in patients who would be classified as IPAH
according to current recommendations has a significant adverse effect on outcomes. This phenotype can
be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and
severely reduced DLCO may represent a further distinct phenotype. These data suggest that randomised
controlled trials of targeted therapies in patients with these phenotypes are required.
This article has an editorial commentary: https://doi.org/10.1183/13993003.00606-2020
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Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a rare condition (estimated incidence <5 million
cases per year) defined haemodynamically as mean pulmonary arterial pressure (mPAP) >20 mmHg, left
atrial pressure ⩽15 mmHg and pulmonary vascular resistance >3 Wood units [1, 2]. It is defined clinically
as the absence of conditions or risk factors associated with the development of precapillary pulmonary
hypertension, including connective tissue disease, congenital heart disease, chronic thromboembolic
disease and lung disease [3]. Several medical therapies have been shown to improve haemodynamics,
exercise capacity and clinical events, and survival has improved significantly over the past three decades
[4–6]. Chronic lung disease-associated pulmonary hypertension (CLD-PH) is common; 90% of patients
with severe COPD have a mPAP >20 mmHg [7]. Significant pulmonary hypertension in association with
lung disease is less common; ⩽5% of COPD patients have mPAP ⩾35 mmHg [8].
Mild lung disease may be present in patients with severe precapillary haemodynamics. This can create
diagnostic uncertainty as to whether a patient has group 1 (pulmonary arterial hypertension (PAH)) or
group 3 (CLD-PH) disease. The recent 6th World Symposium on Pulmonary Hypertension (WSPH)
suggested that patients with coexisting lung disease should be diagnosed with PAH when pulmonary
hypertension is moderate–severe, when only modest spirometric or parenchymal abnormalities are present
and when diffusion capacity of the lung for carbon monoxide (DLCO) is low with respect to obstructive or
restrictive lung function [7].
There are few data defining survival and treatment response in patients with mild lung disease who fulfil the
diagnostic criteria for IPAH suggested by the 6th WSPH. We hypothesised that even mild lung disease and/
or low gas transfer have a negative effect on outcomes in patients with a diagnosis of IPAH. Therefore, we
performed a study of characteristics, survival and response to therapy of patients who had been assigned a
diagnosis of IPAH at a large pulmonary hypertension referral centre over an 18-year period.
Methods
Patients who had been assigned a diagnosis of IPAH or heritable PAH or CLD-PH between February 2001
and January 2019 at our centre were identified from the ASPIRE (Assessing the Spectrum of Pulmonary
Hypertension Identified at a Referral Centre) registry, a database consisting of consecutive patients referred
to the Sheffield Pulmonary Vascular Disease Unit (Sheffield, UK), who undergo multimodality assessment
and multidisciplinary team discussion, as previously described [9]. Radiology images and reports, lung
function tests, pulmonary haemodynamics and clinical correspondence were retrieved, blinded to outcomes.
Computed tomography (CT) images had been reported at the time of diagnosis by experienced pulmonary
vascular radiologists, blinded to haemodynamics and spirometry, using a qualitative assessment of the extent
of parenchymal lung disease: none, minor, mild, moderate or severe. In the absence of moderate to severely
abnormal spirometry (defined as forced expiratory volume in 1 s (FEV1) <60% and/or forced vital capacity
(FVC) <70%), patients with a diagnosis of IPAH or heritable PAH who had no parenchymal lung disease
were termed IPAHno-LD while those who had minor or mild emphysema or fibrosis on their original CT
report were termed IPAHmild-LD. Patients with moderate to severely abnormal spirometry and/or those with
moderate or severe parenchymal lung disease were defined as CLD-PH. Patients with pulmonary
hypertension caused by respiratory disease other than COPD, emphysema or interstitial lung disease (ILD)
were excluded. In addition, patients with two or more radiological features of possible pulmonary
veno-occlusive disease (PVOD: centrilobular ground-glass opacities, mediastinal lymphadenopathy and
interlobular septal lines) were excluded [10]. Smoking status and history were retrieved from clinical notes.
Quality of life was assessed by emPHasis-10 score [11] (scored out of 50; lower score represents lower
symptom burden).
Mortality data
Mortality data were obtained from systems linked to the National Health Service Personal Demographics
Service (PDS), which is updated when a death is registered in the UK. Patients who emigrated (n=3) were
excluded, as were patients without a record on the PDS (n=2). Patients undergoing lung transplantation were
censored at the time of surgery, and mortality data were collected using a census date of May 31, 2019.
Follow-up
Two follow-up time points were used to assess treatment response: first follow-up beyond 90 days of
diagnosis and first follow-up between 9 and 15 months in patients receiving oral combination therapy
within 6 months of diagnosis. The latter time point was used to enable comparison between patients who
had received a similar therapeutic approach.
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Statistics
Statistical analysis was performed using SPSS (v25; IBM, Armonk, NY, USA) and GraphPad Prism (v8;
GraphPad, La Jolla, CA, USA). Unless otherwise specified, continuous data are presented as mean±SD
(compared using paired/unpaired t-tests) or median (interquartile range) for nonparametric data (compared
using Wilcoxon signed-rank/Mann–Whitney U-tests). Frequencies were compared using the Chi-squared
test. Multivariate Cox regression was performed in a forward direction on parameters with a p-value <0.2 at
univariate analysis. To allow comparison at univariate and multivariate analysis, continuous variables were
scaled to the mean. For other statistical tests, a p-value of <0.05 was considered significant. Kaplan–Meier
survival curves were compared using the log-rank test, truncated at 5 years. Where appropriate, 95%
confidence intervals were derived for median values using a bootstrap resampling technique.
Ethics
Ethical approval was granted by Sheffield Teaching Hospitals NHS Foundation Trust (STH14169) and
approved by the National Research Ethics Service (16/YH/0352).
Results
Of 5643 patients diagnosed with all forms of pulmonary hypertension, 493 incident patients were
identified who had a diagnosis of either idiopathic or heritable PAH (hereafter grouped as IPAH, who
formed the main study population) (figure 1). Following reassessment of patients assigned a diagnosis of
Diagnosis of pulmonary
hypertension
n=5643
Included in study
n=1143
IPAHno-LD
n=303
IPAHDLCO<45
n=79
IPAHDLCO≥45
n=174
No 
DLCO recorded
n=50
COPD/emphysema 66%
Interstitial lung disease 20%
Mixed 14%
IPAHmild-LD
n=190
Group 3 (CLD-PH)
n=650
Group 5 (miscellaneous)
n=146
Group 2 (LHD-PH)
n=1178
Group 4 (CTEPH)
n=922
Other group 3 (CLD-PH) causes
including OHS/OSA or no RHC
n=377
Group 1 (PAH) other than
IPAH/HPAH
n=1877
FIGURE 1 Flow chart demonstrating selection of patients for participation in study. CTEPH: chronic thromboembolic pulmonary hypertension;
LHD-PH: pulmonary hypertension due to left heart disease; CLD-PH: chronic lung disease-associated pulmonary hypertension; OHS: obesity
hypoventilation syndrome; OSA: obstructive sleep apnoea; RHC: right heart catheterisation; PAH: pulmonary arterial hypertension; IPAH:
idiopathic PAH; HPAH: heritable PAH; IPAHno-LD: IPAH with no lung disease; IPAHmild-LD: IPAH with mild lung disease; IPAHDLCO⩾45: IPAH with no
lung disease with DLCO ⩾45% pred; IPAHDLCO<45: IPAH with no lung disease with DLCO <45% pred.
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IPAH, 303 had no evidence of parenchymal lung disease (IPAHno-LD) while 190 had minor or mild
parenchymal lung disease (IPAHmild-LD). Baseline right heart catheterisation data were available in 98%,
spirometry in 97% and DLCO in 83% of patients with IPAHno-LD and IPAHmild-LD.
Comparison of IPAHno-LD versus IPAHmild-LD
Patients with IPAHno-LD were younger (mean age 53 versus 70 years; p<0.0001), had a female
predominance (73% versus 47%; p<0.0001), a higher mean mPAP and mixed venous oxygen saturations
(mPAP 55 mmHg versus 50 mmHg, mixed venous oxygen saturation (SvO2) 60% versus 62%; both p<0.05)
and were less likely to have a smoking history than patients with IPAHmild-LD (p<0.0001) (table 1).
Spirometric volumes were well preserved in patients with IPAHno-LD and IPAHmild-LD. Patients with
IPAHno-LD had significantly better survival than patients who had IPAHmild-LD (1- and 5-year survival
95% and 70% versus 78% and 22%, respectively; p<0.0001) (figure 2). When patients with IPAHno-LD and
IPAHmild-LD were analysed together in a multivariate model, independent predictors of higher mortality
were increasing age, lower DLCO % predicted, lower incremental shuttle walking test distance (ISWD) and
a diagnosis of IPAHmild-LD (table 2). In view of the different forms of parenchymal lung disease
encompassed by IPAHmild-LD, this multivariate model was reanalysed using data for the emphysema or
interstitial lung disease subtypes separately. Increasing age, lower ISWD and a diagnosis of IPAHmild-LD
remained as independent predictors of mortality. There was no significant difference in survival between
patients with IPAHmild-LD who had emphysema or ILD (supplementary figure S1). Baseline demographics
and haemodynamics of these groups were also very similar (supplementary table S1). Lung function data
for subtypes of IPAHmild-LD are also shown in supplementary table S1.
TABLE 1 Baseline demographics and maximal treatment data
IPAHno-LD IPAHmild-LD p-value
Subjects n 303 190
Female 73 47 <0.0001
Age years 53±17 70±10 <0.0001
WHO FC I/II/III/IV 0/21/60/19 0/9/56/35
BMI kg·m−2 29±6 28±6 0.15
mRAP mmHg 11±6 11±5 0.39
mPAP mmHg 55±13 50±9 <0.0001
PAWP mmHg 10±3 11±3 0.10
PVR WU 11.9±5.8 11.1±4.5 0.10
SvO2 % 62±9 59±9 0.02
Cardiac output L·min−1 4.3±1.6 4.0±1.4 0.04
Cardiac index L·min−1·m−2 2.3±0.8 2.2±0.7 0.07
FEV1 % pred 89±15 89±17 0.64
FVC % pred 100±17 103±18 <0.05
FEV1/FVC 75±9 68±8 <0.0001
DLCO % pred 56±20 30±13 <0.0001
ISWD m 210 (80, 360) 80 (40, 180) <0.0001
Current smokers 40 82 <0.0001
Smoking history pack-years 25±17 32±18 0.03
Maximal treatment#
None 1 1
CCB 5 1
Oral monotherapy 19 34
Combination oral 44 50
Prostanoid±oral 31 14
Data are presented as %, mean±SD or median (interquartile range), unless otherwise stated. IPAH:
idiopathic pulmonary arterial hypertension; IPAHno-LD: IPAH with no lung disease; IPAHmild-LD: IPAH with
mild lung disease; WHO FC: World Health Organization functional class; BMI: body mass index; mRAP:
mean right atrial pressure; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge
pressure; PVR: pulmonary vascular resistance; WU: Wood units; SvO2: mixed venous oxygen saturation;
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for
carbon monoxide; ISWD: incremental shuttle walking test distance; CCB: calcium-channel blockers.
#: received during the study.
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Effect of DLCO on survival in IPAHno-LD
A bimodal distribution of DLCO % predicted (modes 30, 65) was observed in patients with IPAHno-LD with
an optimal cut-point of 45% (supplementary figure S2). Patients with IPAHno-LD who had a DLCO <45%
pred (IPAHDLCO<45) were older (mean 65 versus 48 years), had a lower mPAP (51 versus 56 mmHg) and a
lower SvO2 (60% versus 63%) than patients with DLCO ⩾45% predicted (IPAHDLCO⩾45) (all p<0.05). Detailed
demographics are shown in supplementary table S2. Those with IPAHDLCO<45 were more likely to have a
history of smoking (52% versus 36%; p<0.05). There was no significant difference in lung volumes (FEV1
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Time years
IPAHno-LD
IPAHmild-LD
p<0.0001
303 265 218 191 155 128
543210
190 138 85 46 27 18
At risk n
IPAHno-LD
IPAHmild-LD
FIGURE 2 Survival from diagnosis in idiopathic pulmonary arterial hypertension with no lung disease
(IPAHno-LD) and with mild lung disease (IPAHmild-LD).
TABLE 2 Univariate and multivariate Cox regression analysis of prognostic factors in patients
with idiopathic pulmonary arterial hypertension with no lung disease (IPAHno-LD) or mild lung
disease (IPAHmild-LD)
Univariate Multivariate
Scaled HR p-value Scaled HR p-value
IPAHmild-LD (ref. IPAHno-LD) 4.287 <0.0001 2.168 <0.0001
Age (years) 2.320 <0.0001 1.432 0.014
Sex (ref. female) 1.549 0.001
Smoking history (ref. none) 2.373 <0.0001
WHO FC III and IV (ref. I and II) 3.246 <0.0001
FEV1 % pred 0.995 0.945
FVC % pred 1.072 0.328
FEV1/FVC 0.767 <0.0001
DLCO % pred 0.340 <0.0001 0.739 0.039
mRAP (mmHg) 1.239 <0.0005
PVR (WU) 0.999 0.986
SvO2 (%) 0.740 <0.0001
Cardiac index (L·min−1·m−2) 0.788 0.003
ISWD (m) 0.434 <0.0001 0.559 <0.0001
For continuous variables, hazard ratios (HR) are scaled to the mean. ref: reference; WHO FC: World Health
Organization functional class; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; DLCO:
diffusing capacity of the lung for carbon monoxide; mRAP: mean right atrial pressure; PVR: pulmonary
vascular resistance; WU: Wood units; SvO2: mixed venous oxygen saturation; ISWD: incremental shuttle
walking test distance.
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88% versus 91%, FVC 100% versus 100%; both p>0.05), but FEV1/FVC ratio was lower (71% versus 76%;
p<0.0001) in patients with IPAHDLCO<45. 1- and 5-year survival was significantly lower in patients with
IPAHDLCO<45 (86% and 45% versus 99% and 84%; p<0.0001) (figure 3); this survival difference persisted
when adjusted for age.
Response to treatment
99% of patients with IPAHno-LD and IPAHmild-LD received PAH therapy; treatment response data are
shown in table 3 and figure 4. Baseline ISWD was significantly higher in IPAHno-LD than IPAHmild-LD:
median 210 m versus 80 m (p<0.0001). There was no significant difference in time to follow-up between
patients with IPAHno-LD and IPAHmild-LD. At both first follow-up and at 1-year assessment in patients
who received combination oral therapy within 6 months of diagnosis, patients with IPAHno-LD
demonstrated significant improvement with respect to ISWD and quality-of-life score (p<0.0001), whereas
patients with IPAHmild-LD did not. In patients receiving oral combination therapy within 6 months of
diagnosis, survival was significantly better in patients with IPAHno-LD compared to patients with
IPAHmild-LD (1- and 5-year survival 98% and 74% versus 71% and 13%; p<0.0001) (figure 5). Patients with
IPAHno-LD and IPAHmild-LD who received oral combination therapy within 6 months of diagnosis and had
1-year follow-up data available had more severe haemodynamics than those who did not; haemodynamic
and treatment data for all patients who had follow-up assessments available are displayed in
supplementary table S3.
In the IPAHno-LD group, significant change (Δ) in ISWD was seen in patients with IPAHDLCO<45 (median
Δ +20 m) and IPAHDLCO⩾45 (Δ +50 m) who received treatment; both p<0.05. Baseline emPHasis-10 scores
were significantly higher in patients with IPAHDLCO<45 than in patients with IPAHDLCO⩾45 (median 38
versus 27; p<0.01). Median change in emPHasis-10 at follow-up was not significant in patients with
IPAHDLCO<45 (ΔemPHasis-10 –4; p=0.08) but was significant in patients with IPAHDLCO⩾45 (ΔemPHasis-10
–4; p<0.05).
Discussion
In the current study we reassessed a large number of patients who had been assigned a diagnosis of IPAH
at a large pulmonary hypertension referral centre. By using radiology reports and lung function from the
time of diagnosis we have identified phenotypes of IPAH with different characteristics, response to therapy
and survival. Specifically, we have demonstrated that the presence of even mild parenchymal lung disease
in patients who have been diagnosed with IPAH (IPAHmild-LD) is associated with a distinct clinical picture
(well-preserved spirometry, low DLCO % pred and severe pulmonary hypertension) and has a large
negative effect on outcomes. In addition, we have observed that a proportion of patients with IPAH with
no parenchymal lung disease and unremarkable spirometry have a low DLCO. Differentiation of IPAH
from CLD-PH represents a continual diagnostic challenge to all involved in the care of patients with
0 1 2 3 4 5
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100
Time years
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IPAHDLCO<45
IPAHDLCO≥45
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79
IPAHDLCO≥45
IPAHDLCO<45 62 42 32 24 17
At risk n
FIGURE 3 Survival in idiopathic pulmonary arterial hypertension patients with no lung disease stratified by
diffusing capacity of the lung for carbon monoxide <45% pred (IPAHDLCO<45) versus ⩾45% pred (IPAHDLCO⩾45).
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pulmonary hypertension. Mild pulmonary hypertension in the context of severe lung disease (assessed
radiologically and/or spirometrically) is common, and easily ascribed to group 3 (CLD-PH). Likewise,
most would agree that patients with severe pulmonary haemodynamics and severe lung disease, where the
severity of pulmonary hypertension is proportionate to the degree of lung disease, also have group 3
disease. The presence of more modest lung disease in patients who fulfil traditional criteria for IPAH
presents greater diagnostic and therapeutic challenges
Survival and response to therapy in IPAHmild-LD
In the current study, survival in patients with IPAHmild-LD was significantly worse than in IPAHno-LD. In
addition, although patients with IPAHno-LD experienced significant improvements in walk distance and
emPHasis-10 score following initiation of PAH therapies, this same improvement was not observed in
patients with IPAHmild-LD. Some retrospective studies of patients with mild-to-moderate lung disease and
severe pulmonary hypertension have reported improved haemodynamics and exercise capacity following
commencement of PAH therapies [12–14]. Conversely, BREWIS et al. [15] failed to demonstrate
improvement in 6-min walk distance (6MWD) or World Health Organization functional class in 118
patients with severe pulmonary hypertension and varying degrees of lung disease following PAH therapy,
while we have previously reported treatment response to pulmonary vascular therapy in only 19% of
patients with severe CLD-PH [16]. Prospective randomised controlled studies (RCTs) of PAH therapies in
patients with CLD-PH due to COPD/emphysema have suffered from methodological weaknesses [17, 18]
or recruited patients with mild pulmonary hypertension [19, 20], although VITULO et al. [21] performed a
RCT in 31 patients with severe CLD-PH due to COPD and demonstrated significant improvements in
pulmonary haemodynamics, but no improvement in 6MWD.
The 6th WSPH task force on CLD-PH recommended that in patients with coexisting lung disease, PAH
should be diagnosed when pulmonary hypertension is moderate–severe, when only modest spirometric
(i.e. FEV1 >60% pred and FVC >70% pred) or parenchymal abnormalities are present and when DLCO is
low with respect to obstructive or restrictive lung function [7]. Using these criteria, patients in our
IPAHmild-LD group would keep their original diagnosis of IPAH. Our observations regarding the effect that
mild parenchymal lung disease has on response to therapy and survival suggests that IPAHmild-LD is a
distinct phenotype and that further prospective studies to assess treatment response in these patients are
TABLE 3 Baseline and follow-up incremental shuttle walking test distance (ISWD) and emPHasis-10 quality-of-life score (E-10)
Subjects IPAHno-LD Subjects IPAHmild-LD Subjects IPAHDLCO<45 Subjects IPAHDLCO⩾45
Baseline and first follow-up
beyond 90 days
ISWD
Baseline m 279 210 (80–360) 159 80 (40–180)**** 71 80 (30–210) 170 260 (130–430)####
ΔISWD m 215 40 (−10–120) 124 0 (−32–30)**** 47 20 (−13–70) 139 50 (−10–160)#
ΔISWD p-value <0.0001 0.90 <0.05 <0.0001
E-10 score
Baseline 84 32 (20–40) 83 32 (26–41) 25 38 (33–44) 55 27 (0–35)##
ΔE-10 64 −4 (−12–3) 65 0 (−5–8)* 19 −4 (−13–2) 43 −4 (−11–3)
ΔE-10 p-value 0.005 0.57 0.08 0.03
Baseline and 1-year follow-up:
patients treated with
combination oral treatment
within 6 months of diagnosis
ISWD
Baseline ISWD m 125 200 (80–340) 76 60 (20–140)****
ΔISWD m 79 40 (−10–140) 32 −20 (−50–50)**
ΔISWD p-value <0.0001 0.83
E-10 score
Baseline E-10 57 34 (22–42) 41 35 (28–41)
ΔE-10 27 −4 (−18–5) 17 −4 (−11–3)
ΔE-10 p-value 0.03 0.19
Data are presented as n or median (interquartile range). IPAH: idiopathic pulmonary arterial hypertension; IPAHno-LD: IPAH with no lung
disease; IPAHmild-LD: IPAH with mild lung disease; IPAHDLCO<45: IPAHno-LD with DLCO <45% pred; IPAHDLCO⩾45: IPAHno-LD with DLCO ⩾45% pred; Δ:
change. *: p<0.05; **: p<0.01; ****: p<0.0001 compared to IPAHno-LD;
#: p<0.05; ##: p<0.01; ####: p<0.0001 compared to IPAHDLCO<45.
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warranted. Recognition of an IPAHmild-LD phenotype also has implications for risk stratification, decisions
regarding transplantation and PAH therapy clinical trial design.
IPAH with DLCO <45%
TRIP et al. [22] observed a bimodal distribution of percentage predicted DLCO in a cohort of 166 patients
diagnosed with IPAH, and demonstrated that a DLCO <45% pred conferred worse survival. While they
included patients who had mild or moderate lung disease, we observed a similar distribution of percentage
predicted DLCO in patients without any lung disease (IPAHno-LD, supplementary figure S2). Subsequently,
OLSSON et al. [23] described a subgroup of patients with IPAH with no parenchymal lung disease but
severely reduced gas transfer. In keeping with these two studies, our cohort of IPAHno-LD patients with
DLCO <45% pred (IPAHDLCO<45) was older, more likely to have a smoking history and had a lower exercise
capacity. Although survival in patients with IPAHDLCO<45 was significantly worse than those with
IPAHDLCO⩾45, significant improvements in ISWD were observed following PAH therapy, unlike in patients
with IPAHmild-LD. The cause of the reduced DLCO in a proportion of IPAH patients is unclear. Pulmonary
veno-occlusive disease is a rare cause of low DLCO and is haemodynamically indistinguishable from PAH
[10]. However, we excluded patients (n=18) where there was a possibility of PVOD based on radiological
assessment. Given the increased frequency of smoking in the IPAHDLCO<45 group it is possible that the
reduced DLCO may represent emphysema not visible on cross-sectional imaging [24]. However, tobacco
smoke has also been shown to cause pulmonary vascular remodelling in animal models, and specifically to
cause damage to the pulmonary capillaries [25]. Therefore, the data from the current study provide further
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FIGURE 4 Change at first follow-up beyond 90 days in a) incremental shuttle walking test distance (ISWD);
b) emPHasis-10 quality-of-life score (E-10). Data are presented as median (95% CI). IPAH: idiopathic
pulmonary arterial hypertension; IPAHno-LD: IPAH with no lung disease; IPAHmild-LD: IPAH with mild lung
disease; IPAHDLCO<45: IPAHno-LD with diffusing capacity of the lung for carbon monoxide (DLCO) <45% pred;
IPAHDLCO⩾45: IPAHno-LD with DLCO ⩾45% pred.
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support for the existence of a vanishing capillary syndrome as proposed by HOEPER et al. [26]. Further
histological data are required to fully explain this phenomenon.
Limitations
This is a retrospective study and hence there were some data availability issues, including first follow-up
ISWD data which was not available in 19% of patients. Patients who were unable to attempt the
incremental shuttle walking test due to their pulmonary hypertension were ascribed a distance of 0 m,
which would minimise any potential bias resulting from missing data. Baseline scores for emPHasis-10
were only available for 34% of patients, since it was only introduced in our centre in 2014. A small
number of patients (3%) with IPAHno-LD and IPAHmild-LD did not have spirometry available and were
categorised based on CT data alone. Parenchymal lung disease assessment was based on qualitative clinical
reports provided by radiologists at the time of initial diagnosis in our unit, and not on fully quantitative
assessments. However, our data demonstrate that “real-world” clinical radiological assessments of the
presence and extent of parenchymal lung disease can be used to identify patient groups with different
outcomes. While our patients now routinely undergo high-resolution CT (HRCT) imaging and CT
pulmonary angiography, some patients did not have specific HRCT imaging and so assessment of lung
parenchyma in these patients may have been more limited. As there was no control group in this study, we
cannot rule out a treatment effect of PAH therapies on patients with IPAHmild-LD.
Conclusion
The presence of even mild parenchymal lung disease in patients who, based on current recommendations,
would be classified as having IPAH has a significant adverse effect on survival and, in this patient cohort,
was associated with a lack of significant improvement in exercise capacity following treatment. Patients
with the phenotype of IPAHmild-LD can be identified using lung function testing and qualitative clinical
description of the presence and extent of parenchymal lung disease on routine radiological reporting. In
addition, a proportion of patients with IPAH and no evidence of lung disease or PVOD have a severely
reduced diffusion capacity. Our data support the need for prospective RCTs in patients with these
phenotypes to assess the effects of PAH therapies on short- and long-term outcomes.
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